SEC Form 4 · accession 0001479290-18-000011
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Abhay Joshi
Officer — Chief Operating Officer
Period of report
Jan 15, 2018
Accepted (ET)
Jan 17, 2018 · 9:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 15, 2018 | F | 4,327 | $34.50 | D | 73,356 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares withheld by and surrendered to the issuer on January 15, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2016 Restricted Stock Award ("RSA") for 12,000 shares. The RSA vests in three equal annual installments from January 15, 2017, subject to Dr. Joshi's Continuous Service on each vesting date.
- F2The fair market value was determined on January 12,2018 per the Company Policy, as this was the last trading day before the vest date.